Company Filing History:
2 out of 3,446 
1 out of 4,671 
1 out of 1,243 
Years Active: 2001-2007
Title: Innovator Spotlight: Michael L. Bittner
Introduction
Michael L. Bittner is a prominent inventor based in Rockville, MD, who has made significant contributions to the field of cancer research. With three patents to his name, Bittner's work focuses on the identification and treatment of aggressive forms of malignant melanoma through innovative genetic methodologies.
Latest Patents
Bittner's latest patents delve into two pivotal areas of cancer research. The first patent addresses the classification of cancers by highlighting the overexpression of marker genes, particularly Wnt5a, which serves as a crucial indicator of more aggressive melanoma forms. This discovery paves the way for improved diagnosis, profiling, and treatment strategies, indicating that inhibition of Wnt5a activity through methods such as anti-sense therapy, gene therapy, and pharmaceutical intervention could prove beneficial.
The second patent centers on quantifying gene relatedness via nonlinear prediction of gene expression. Bittner's method constructs nonlinear models to evaluate gene relationships, using various modeling techniques, including full-logic and neural networks. A user-friendly graphical interface presents the results, allowing for a clear visual analysis of each gene's contribution to relatedness and model prediction.
Career Highlights
Throughout his career, Michael L. Bittner has been associated with notable organizations such as the United States Department of Health and Human Services and Agilent Technologies, Inc. His innovative research and patents have significantly impacted the understanding and treatment of cancer.
Collaborations
Bittner has collaborated with esteemed colleagues, including Yidong Chen and Edward R. Dougherty, contributing to a rich environment of research and innovation within the fields of genetics and cancer treatment.
Conclusion
Michael L. Bittner stands out as a remarkable inventor in cancer research, with his groundbreaking patents leading the way for advancements in diagnosis and treatment. His continued contributions to the field promise to enhance the understanding of genetic markers in malignant melanoma, paving the path for future innovations.